In September 2016, a grieving mother, pushed to the brink by the death of her newborn son, sent a desperate, final email to Mead Johnson, a titan of the infant formula industry. Her message was as raw as it was clear: "REMOVE ME FROM YOUR LIST!!!! DO NOT EMAIL OR MAIL ME ANY MORE!" The cause of her fury was the death of her son from necrotizing enterocolitis (NEC), an aggressive, often fatal condition where intestinal tissue dies, allowing infection to ravage a premature infant’s body. She blamed the company’s cow’s-milk-based pre-term formula.
Inside the corporate offices of Mead Johnson, the reaction was clinical and swift. An internal memo reviewed the complaint, cited "extensive quality and safety checks," and concluded there was "not a reasonable possibility" that the product had caused the death. The directive was blunt: "No further investigation is needed. This file can be closed."
That singular decision—to categorize a grieving parent’s report as a non-issue—exemplifies a systemic pattern within the infant formula industry. As a wave of litigation sweeps across the United States, internal documents and court testimonies are revealing a troubling reality: when babies get sick or die, the burden of investigation and reporting falls almost entirely on the manufacturers themselves.
The Regulatory Loophole: A "Reasonable Possibility"
Under federal regulations, manufacturers are required to investigate complaints that suggest a potential health hazard. However, the threshold for reporting these findings to the Food and Drug Administration (FDA) is remarkably narrow. Companies are only mandated to notify the FDA within 15 days if they conclude there is a "reasonable possibility of a causal relationship" between their formula and an infant’s death.
If a company decides that a death was caused by something other than their product—or that the link is merely speculative—they are under no obligation to inform federal regulators. In practice, this means the very entities facing potential liability for these deaths are the ones acting as the final judge of whether those deaths merit government attention.
The result is a regulatory silence that has persisted for decades. KFF Health News submitted Freedom of Information Act requests to the FDA, seeking records of such notifications since the year 2000. The response was startling: the agency could not locate a single record of an infant formula manufacturer reporting a death to the FDA under these specific regulatory requirements.
A Chronology of Concealed Conflict
The history of this issue is marked by a recurring cycle of parental alarm, corporate dismissal, and subsequent legal discovery.
- 2010: Internal documents from Abbott Laboratories, later revealed in the Gill v. Abbott case, show scientists acknowledging that NEC is the most severe gastrointestinal complication of prematurity, with bovine-based fortifiers identified as a "primary risk factor."
- 2016: The aforementioned case involving the distraught mother occurred, where Mead Johnson closed the file on her son’s death without reporting it to the FDA, citing no "reasonable possibility" of causation.
- 2020: Mead Johnson’s internal strategy documents, surfacing in the Whitfield litigation, outlined a marketing plan focused on "Branding NICU Babies," highlighting the intense corporate competition to secure hospital contracts.
- 2024: A series of landmark trials reached courtrooms across the U.S. In Watson v. Mead Johnson, a jury initially awarded $60 million in damages. In Gill v. Abbott, a jury awarded $495 million, a verdict later upheld by an appeals court that described Abbott’s conduct as "significantly reprehensible."
Throughout these years, company officials—including medical directors—consistently testified in depositions that they had never, in their entire tenures, concluded that a death was causally linked to their products.
Supporting Data: The Scale of the Tragedy
The human cost of NEC is staggering. Between 2017 and 2023, approximately 2,300 newborns in the United States died from the condition—an average of nearly one death every single day. While the federal database tracking these deaths does not explicitly link them to formula, the rise in litigation highlights the persistent question of whether these products contribute to the disease’s development in vulnerable, premature infants.
As of January 2025, there were roughly 1,760 NEC-related lawsuits pending against Abbott Laboratories alone. Despite these numbers, the industry maintains a firm stance. Abbott spokesperson Scott Stoffel and Mead Johnson representatives argue that scientific consensus does not support a causal link between their formulas and NEC. They point to the "multifaceted" nature of the disease and emphasize that, in the absence of human breast milk, specialized preterm formula is a life-saving necessity.
Official Responses and the "Fox in the Henhouse"
The industry’s defense often relies on the assertion that their internal records are subject to FDA audits. John Wallingford, a former FDA official turned paid expert for Abbott, testified that while Abbott may not have formally reported specific deaths, the complaints were contained within company files that FDA inspectors could have reviewed during annual audits.
However, legal experts and critics argue that internal "complaint files" are not a substitute for the public transparency and regulatory oversight required of other medical industries. The irony of the situation was not lost on plaintiff’s counsel Kevin Carnie Jr., who during the Whitfield trial famously compared the current regulatory environment to the "fox guarding the henhouse."
The FDA’s response to these concerns has been measured. The agency insists that infant formula safety remains a "top priority," yet it confirms that, unlike drugs and medical devices, there is no public database where manufacturers’ adverse event reports for formula are disclosed. Furthermore, the agency’s reporting requirements for drugs are far more rigorous, often requiring the reporting of "serious and unexpected" events regardless of whether they are definitively considered "drug-related."
Implications: A Conflict of Interest at the Top
The issue of regulatory capture has been raised by the revelation that the current acting head of the FDA, Kyle Diamantas, previously represented Abbott in the very lawsuits—Gill and Whitfield—that exposed these reporting failures. While the Department of Health and Human Services (HHS) notes that Diamantas has complied with all ethics laws and observed a recusal period from matters involving Abbott, the overlap has fueled public skepticism regarding the agency’s impartiality.
The implications for the medical community are profound. Doctors rely on these companies for data regarding the safety and efficacy of their products. Yet, internal emails suggest a culture of skepticism toward reports from hospitals. In one instance, a Mead Johnson medical director responded to a hospital’s report of three infant deaths by suggesting there was "no science basis" for the concern, despite the hospital’s clear observation of a correlation between formula use and the NEC cases.
Conclusion: The Need for Transparency
The battle over NEC and infant formula is far from over. With the Whitfield case heading for a new trial and various other cases moving through the court system, the judiciary is becoming the de facto regulator of the industry.
The core of the conflict lies in the disparity between the corporate need to protect a brand and the public health imperative to report potential risks. As long as the manufacturers of infant formula hold the power to decide which deaths are worth reporting to the government, the "reasonable possibility" standard will remain a high wall that keeps critical safety information away from the public and the regulators tasked with protecting the most vulnerable among us.
For the parents who have lost their children, the legal victories and the exposure of internal documents are not just about financial compensation—they are about the hope that the "silent" deaths of the past will finally force a change in a system that has, for too long, prioritized corporate protection over the transparency required to prevent future tragedies.
